EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Amino acid and protein Sources: 16

5-HTP (5-hydroxytryptophan)

Also called: 5-hydroxytryptophan, 5-hydroxy-L-tryptophan, L-5-hydroxytryptophan, L-5-HTP

5-HTP (5-hydroxy-L-tryptophan) is the immediate precursor of serotonin, made in the body from the amino acid L-tryptophan. Supplement 5-HTP comes from Griffonia simplicifolia seed, chemical synthesis, or whole-cell biosynthesis in Escherichia coli or Saccharomyces cerevisiae.

Category
Amino acid and protein
Forms
5-Hydroxy-L-tryptophan from Griffonia simplicifolia seed, synthetic L-5-HTP, or whole-cell biosynthesis (E. coli, S. cerevisiae)
Strongest evidence
C Limited
Reviewed
2026-10-30

Class 2 Moderately studied in people. No review we found counts RCTs of 5-HTP alone. We confirmed five randomized trials of oral 5-HTP versus placebo or no supplement (24 to 166 participants); a double-blind placebo-controlled trial in 45 patients was not counted because randomization is not stated. [5]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

7 topics studied3 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what 5-HTP (5-hydroxytryptophan) does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for 5-HTP (5-hydroxytryptophan), evidence grade and finding
Topic studiedGradeWhat the evidence shows
Depression (placebo-controlled trials)CA Cochrane review located 108 trials, but only two (64 patients) of 5-HTP or tryptophan met quality criteria; they favored the supplements over placebo, but evidence was of insufficient quality to be conclusive. [3]
Depression (2020 systematic review)CA review of 13 studies (7 meta-analyzed) reported a pooled remission rate of 0.65 with high heterogeneity; the authors rated current studies relatively weak because few include placebo groups. [4]
Fatigue in inflammatory bowel disease in remissionXIn a 13-hospital crossover RCT (166 patients; 100 mg twice daily for 8 weeks), 5-HTP raised serum 5-HTP and serotonin but did not reduce fatigue better than placebo. [5]
Chronic tension-type headacheCIn a double-blind RCT (78 patients; 300 mg/day for 8 weeks), 5-HTP did not change headache days or intensity versus placebo, though analgesic use fell. [6]
Sleep quality in older adultsCA single-blinded 12-week RCT (30 older adults, 66 ± 3 years; 100 mg/day versus no supplement) found improved subjective sleep scores in poor sleepers only. [7]
Anxiety disordersCA double-blind trial in 45 patients found a moderate reduction of symptoms on two scales with 5-HTP, while clomipramine improved all rating scales versus placebo. [8]
Menopausal hot flashesCA small double-blind trial in 24 postmenopausal women found no significant effect of 150 mg/day 5-HTP on objectively recorded hot-flash frequency; the author called it preliminary. [9]

Main constituents: 5-Hydroxy-L-tryptophan, the immediate precursor of serotonin (5-hydroxytryptamine) in its biosynthesis from L-tryptophan [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • IBD fatigue trial: 100 mg oral 5-HTP twice daily for 8 weeks. [5]
  • Tension-type headache trial: 300 mg/day for 8 weeks. [6]
  • Sleep trial in older adults: 100 mg/day for 12 weeks. [7]
  • Health Canada monograph (August 28, 2024), adults 18+: 150–300 mg/day (mood), 100–200 mg/day (sleep disturbances), 300–400 mg/day (fibromyalgia), 200–600 mg/day (migraine), with no more than 300 mg per single dose for fibromyalgia and migraine. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Health Canada: consult a health care practitioner before use if pregnant or breastfeeding …

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    3 listed

    Antidepressants; Carbidopa and serotonergic products; Carbidopa

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    1 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Health Canada monograph (August 28, 2024), adults 18+: mood 150–300 mg/day; sleep disturbances 100–200 mg/day; fibromyalgia 300–400 mg/day …

    Details and sources
  • An eosinophilia-myalgia syndrome (EMS)-like illness occurred in a family exposed to L-5-HTP: one member had EMS and two had eosinophilia; their 5-HTP contained an impurity absent from other samples, and eosinophilia resolved after switching. [11]
  • 'Peak X', reported in EMS case-implicated 5-HTP, is a family of contaminants (234 Da); all eight commercial 5-HTP samples analyzed by HPLC-MS contained three or more of them. [12]
  • Peak X1 was identified as 4,5-tryptophan-dione, a putative neurotoxin, in case-implicated 5-HTP and six over-the-counter samples (0.5–10.3% of the case-implicated amount). [13]
  • A 2004 safety review stated that no definitive cases of toxicity had emerged, with one possible unresolved case, and that peak X reported in some samples lacks credibility due to chromatographic artifacts and infinitesimal concentrations. [1]
  • The Cochrane review noted that the possible association between 5-HTP or tryptophan and the potentially fatal EMS has not been elucidated. [3]
  • Health Canada: do not use with scleroderma; stop use and consult a practitioner for skin hardening, muscle or joint pain or stiffness, tremors, agitation or confusion, or increased heart rate; drowsiness may occur. [2]
  • With carbidopa, nausea and vomiting were dose-dependent, causing dropout of 6.6% at 100 mg and 45.5% at 300 mg 5-HTP. [14]
  • After a single dose, 19.6% of participants in the 5-HTP group had adverse events of fatigue, nausea or vomiting. [10]
Interactions

Interactions

5-HTP (5-hydroxytryptophan)
From the table below 3 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of 5-HTP (5-hydroxytryptophan)
WithWhat happens
AntidepressantsHealth Canada's 5-HTP monograph contraindication: do not use if you are taking antidepressants. [2]
Carbidopa and serotonergic productsHealth Canada's 5-HTP monograph: consult a health care practitioner before use if taking carbidopa or health products with serotonergic activity, such as mood balance supplements, dextromethorphan cough medication, pain killers, or medications for nausea or migraine. [2]
CarbidopaCombining 5-HTP with carbidopa is expected to increase bioavailability for brain penetration by reducing peripheral decarboxylation of 5-HTP to serotonin; with carbidopa, nausea and vomiting rose with 5-HTP dose. [14]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Peak X-family contaminants were detected by HPLC-MS in all eight commercial 5-HTP samples tested in one study. [12]
Regulation

Regulatory status

  • Canada: Health Canada's 5-HTP monograph (August 28, 2024) lists source materials, uses and doses for adults 18 and older. [2]
  • US: FDA's published NDI notification list has 1 entry naming 5-HTP (5-hydroxytryptophan, 5-hydroxy-L-tryptophan): NDI 1100, submitted 2018-11-12. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [15]
  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [16]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • 5-Hydroxy-L-tryptophan (L-5-HTP), immediate precursor of serotonin Amino acids, amines and peptides (amino acid derivative) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 1 entry naming 5-HTP (5-hydroxytryptophan, 5-hydroxy-L-tryptophan): NDI 1100, submitted 2018-11-12. Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P2]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of 5-HTP (5-hydroxytryptophan) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Antidepressants: Health Canada's 5-HTP monograph contraindication: do not use if you are taking antidepressants. [P4]
  • Carbidopa and serotonergic products: Health Canada's 5-HTP monograph: consult a health care practitioner before use if taking carbidopa or health products with serotonergic activity, such as mood balance supplements, dextromethorphan cough medication, pain killers, or medications for nausea or migraine. [P4]
  • Carbidopa: Combining 5-HTP with carbidopa is expected to increase bioavailability for brain penetration by reducing peripheral decarboxylation of 5-HTP to serotonin; with carbidopa, nausea and vomiting rose with 5-HTP dose. [P5]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • Klarskov et al. (1999): peak X in EMS case-implicated 5-HTP is a family of contaminants of the same molecular weight (234 Da); all eight commercial samples tested by HPLC-MS contained three or more. [P6]
  • Klarskov et al. (2003): contaminant X1 was identified as 4,5-tryptophan-dione by accurate-mass LC-MS and MS/MS against an authentic standard; it was present in six over-the-counter samples. [P7]
  • Michelson et al. (1994): 5-HTP linked to EMS-like illness in one family contained an impurity not present in samples used by other patients. [P8]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P9]
  • HPLC-UV / LC-MS screen for peak X-family contaminants, including 4,5-tryptophan-dione — Peak X contaminants were found in EMS case-implicated 5-HTP and in commercial samples. [P7]

Supply and conservation

  • Health Canada lists source materials: Griffonia simplicifolia seed, synthetic L-5-HTP, and whole-cell biosynthesis using Escherichia coli or Saccharomyces cerevisiae. [P4]

Absorption in people

  • In five patients with myoclonic disorders given oral L-5-HTP with a decarboxylase inhibitor, systemic availability was 47–84% (mean 69.2%); peak plasma levels came 1.8–3.3 h after dosing, with linear kinetics. [P10]
  • With carbidopa in 15 healthy men, 5-HTP kinetics fit a one-compartment model with lag time; mean oral clearance was 28 L/h. [P5]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Health Canada monograph (August 28, 2024), adults 18+: mood 150–300 mg/day; sleep disturbances 100–200 mg/day; fibromyalgia 300–400 mg/day; migraine 200–600 mg/day; weight management 750–900 mg/day; no more than 300 mg per single dose for fibromyalgia, migraine and weight management. [P4]

Pregnancy and breastfeeding

  • Health Canada: consult a health care practitioner before use if pregnant or breastfeeding; weight-management products carry the contraindication 'do not use if you are pregnant'. [P4]

Sources for this profile

  1. Das YT, et al. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004;150(1):111-22 (PMID 15068828), 2004-04-15. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  4. Health Canada, NNHPD. Natural health product monograph: 5-HTP (date August 28, 2024), 2024-08-28. webprod.hc-sc.gc.ca
  5. Smarius LJ, et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J Psychopharmacol 2008;22(4):426-33 (PMID 18308795), 2008-06. pubmed.ncbi.nlm.nih.gov
  6. Klarskov K, et al. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Adv Exp Med Biol 1999;467:461-8 (PMID 10721089), 1999. pubmed.ncbi.nlm.nih.gov
  7. Klarskov K, et al. Structural characterization of a case-implicated contaminant, 'Peak X,' in commercial preparations of 5-hydroxytryptophan. J Rheumatol 2003;30(1):89-95 (PMID 12508395), 2003-01. pubmed.ncbi.nlm.nih.gov
  8. Michelson D, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21(12):2261-5 (PMID 7699627), 1994-12. pubmed.ncbi.nlm.nih.gov
  9. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  10. Magnussen I, Nielsen-Kudsk F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacol Toxicol (Copenh) 1980;46(4):257-62 (PMID 6966118), 1980-04. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. Das YT, et al. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004;150(1):111-22 (PMID 15068828), 2004-04-15. pubmed.ncbi.nlm.nih.gov
  2. Health Canada, NNHPD. Natural health product monograph: 5-HTP (date August 28, 2024), 2024-08-28. webprod.hc-sc.gc.ca
  3. Shaw K, et al. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;(1):CD003198 (PMID 11869656), 2002. pubmed.ncbi.nlm.nih.gov
  4. Javelle F, et al. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutr Rev 2020;78(1):77-88 (PMID 31504850), 2020-01-01. pubmed.ncbi.nlm.nih.gov
  5. Truyens M, et al. Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: a randomized controlled trial. Gastroenterology 2022;163(5):1294-1305.e3 (PMID 35940251), 2022-11. pubmed.ncbi.nlm.nih.gov
  6. Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache 2000;40(6):451-6 (PMID 10849040), 2000-06. pubmed.ncbi.nlm.nih.gov
  7. Sutanto CN, et al. The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: a randomized controlled trial. Clin Nutr 2024;43(3):593-602 (PMID 38309227), 2024-03. pubmed.ncbi.nlm.nih.gov
  8. Kahn RS, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;2(1):33-45 (PMID 3312397), 1987-01. pubmed.ncbi.nlm.nih.gov
  9. Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas 2010;65(4):383-5 (PMID 20031347), 2010-04. pubmed.ncbi.nlm.nih.gov
  10. Jackson E, et al. The effect of 5-hydroxytryptophan, a serotonin precursor, on adults with high levels of Attention Deficit Hyperactivity Disorder traits: a randomised, controlled trial. PLoS One 2026;21(5):e0349512 (PMID 42160304), 2026-05-20. pubmed.ncbi.nlm.nih.gov
  11. Michelson D, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21(12):2261-5 (PMID 7699627), 1994-12. pubmed.ncbi.nlm.nih.gov
  12. Klarskov K, et al. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Adv Exp Med Biol 1999;467:461-8 (PMID 10721089), 1999. pubmed.ncbi.nlm.nih.gov
  13. Klarskov K, et al. Structural characterization of a case-implicated contaminant, 'Peak X,' in commercial preparations of 5-hydroxytryptophan. J Rheumatol 2003;30(1):89-95 (PMID 12508395), 2003-01. pubmed.ncbi.nlm.nih.gov
  14. Smarius LJ, et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J Psychopharmacol 2008;22(4):426-33 (PMID 18308795), 2008-06. pubmed.ncbi.nlm.nih.gov
  15. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  16. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in amino acid and protein: Beta-alanine · BPC-157 · Branched-chain amino acids (BCAAs) · Carnosine (L-carnosine) · Collagen peptides · Creatine · Glutathione · L-arginine · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.